Proactive Investors - Run By Investors For Investors

Immupharma raises £8.3mln for Lupuzor trials & early stage pipeline

Immupharma (LON:IMM) chairman Tim McCarthy tells Proactive Investors about the market opportunity for potential blockbuster drug Lupuzor.

“What is unusual I think about Immupharma is we are in the very fortunate position of having a very late stage product, in Lupuzor, in phase III which we own 100 percent of the rights to" he said.

McCarthy expects to update the markets in the next couple of months with progress of Lupuzor through its Phase III clinical trials in the U.S. and Europe.

Meet Sayona Mining Ltd, Lithium Power International Ltd, Elementos, Tyranna Resources and Argent Minerals Ltd at our event, Melbourne, 25 July 2017. Register here »
Why Invest In ImmuPharma PLC? Read More Here

Register here to be notified of future ImmuPharma PLC articles
View full IMM profile View Profile

ImmuPharma PLC Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use